Science – Technology Team

Randall Haskin -- Founder/CEO -- Mr. Haskin received a Masters Degree

from the University of California system in Organic Chemistry, Biology, Physics and Philosophy
in 1969. He is the Co-Founder of Cannasafe Analytics the first ISO 17025 accredited cannabis
laboratory in the country.

Marvin Hausman MD
Dr. Hausman received his M.D. degree from New York University School of Medicine in 1967
and is a Board Certified Urological Surgeon. He has over 30 years of drug development and
clinical care experience at various pharmaceutical companies, including working in conjunction
with Bristol Myers International, Mead Johnson Pharmaceutical Co., and Medco Research,
Inc. Dr. Hausman served on the board of directors of OXIS International, Inc. from March 2002
to November 2003. Subsequently, Dr. Hausman was reappointed to the board of directors of
OXIS in August 2004. On December 10, 2004, the board of directors appointed Marvin S.
Hausman, M.D. to serve as Chairman of the Board, Acting Chief Executive Officer and Acting
Chief Financial Officer of OXIS. In February 2005, Dr. Hausman ceased to be the Chief
Executive Officer of OXIS. In September 2006, Dr. Hausman was again appointed to serve as
President and Chief Executive Officer by the board of directors of OXIS. In June 2008, Dr.
Hausman resigned as President, Chief Executive Officer, Acting Principal Accounting and
Financial Officer and Chairman of the Board of OXIS International, Inc. and as a director. Dr.
Hausman served as a director and as Chairman of the Board of Axonyx Inc., a biotechnology
company developing drugs for Alzheimer’s disease, from 1997 until the merger of Axonyx into
Torrey Pines Therapeutics in October 2006, and had served as President and Chief Executive
Officer of Axonyx from 1997 until September 2003 and March 2005, respectively. Dr. Hausman
was a cofounder of Medco Research Inc., a pharmaceutical biotechnology company
specializing in adenosine products which was subsequently acquired by King Pharmaceuticals.
He has also served as a director of Arbios Technologies, Los Angeles, CA from 2003 - 2005
and of Regent Assisted Living, Inc., Portland, OR, from 1996 -2001.

Dr. Hausman has done residencies in General Surgery at Mt. Sinai Hospital in New York, and in
Urological Surgery at U.C.L.A. Medical Center in Los Angeles. He also worked as a Research
Associate at the National Institutes of Health, Bethesda, Maryland. He has been a Lecturer,
Clinical Instructor and Attending Surgeon at the U.C.L.A. Medical Center Division of Urology
and Cedars Sinai Medical Center, Los Angeles. He has been a Consultant on Clinical/
Pharmaceutical Research to various pharmaceutical companies, including Bristol Meyers
International, Mead - Johnson Pharmaceutical Company, Medco Research, Inc., and E.R.
Squibb. Dr. Hausman is President of Northwest Medical Research Partners, Inc. a firm
specializing in the identification and acquisition of breakthrough pharmaceutical and
nutraceutical products. Dr. Hausman’s experience as a medical doctor who also has extensive
experience with pharmaceutical and biotechnology companies, both as an executive and as a
director, served as a basis for his qualification to be a member of the scientific advisory board.

Kent Crowley, Pharm.D, ABAAHP, FAARFM, Director, Dr.

Crowley received his Doctorate of Pharmacy from the University of California San Francisco in
1983. He completed his residency with Kaiser Permanente, Los Angeles, CA. and received a
Fellowship in Metabolic and Nutritional Medicine 2011. Dr. Crowley is Board-certified Pharm.D.
through the American Academy of Anti-Aging Medicine. During his 34 years in practice, he has
worked in primary research at University California Irvine, Dept. of Pediatrics, Division of Child
Development, involved in the development of several drugs; he holds two patents in neuropathic
pain and a patent-pending buccal delivery system incorporating cannabis. Dr. Crowley currently
is the Director of R&D at Silver State Trading in Sparks, NV, a 40,000 sq.ft. permitted Clean
Green cannabis cultivation and production facility. He serves as the CMO for the Palliative Care
Corporation in Huntington Beach, CA, where he works with patients and physicians
incorporating cannabis in disease state treatment and symptoms management, whether as a
primary treatment or complementary to traditional and/or other modalities. Dr. Crowley is a
member of the Society of Cannabis Clinicians and serves on the Research Subcommittee.

Guillermo Moreno-Sanz PhD -Pharmacologist with a strong background

in organic chemistry and biochemistry and extensive expertise in endocannabinoid
pharmacology with outstanding publication record. Leader of international and multidisciplinary
teams as a project manager in a time- and costeffective manner. Expertise on pharmacological
and ADME characterization of small-drug, pre-clinical candidates. Consultant for the American
National Academies of Sciences on cannabis and responsible for managing the industry-
sponsored research projects at the Piomelli lab in UC Irvine. Education Complutense University
of Madrid, Spain. Ph.D., Neuropharmacology. 2010 University of Zaragoza, Spain. B.S.,
Organic Chemistry 2003 University of Zaragoza, Spain. B.S., Biochemistry 2002 Relevant
Technical Skills  In vivo pharmacology  Gas Chromatography  Cannabinoid pharmacology
 Lipid extraction  HPLC, UPLC  Endocannabinoid pharmacology  ADME studies  Mass
spectroscopy  Cannabis chemistry  PK/PD studies  Real Time PCR  Cannabis
therapeutics Relevant Business and Social Skills  Led multidisciplinary teams  Project
management  Oral communications  Statistical analysis  Mentoring students  Written
communications  Grantsmanship Bio-tech consultancy  Cannabis consultancy Educational
and Professional Development Academic Liaison Cannabis Chemistry Subdivision (CANN).
Division of chemical health and safety (CHAS). American Chemistry Society (ACS).

Oct 2015- Present

Assistant Project Scientist. University of California, Irvine Department of Anatomy &
Neurobiology. Piomelli lab. Acting Mgr of the Agilent-UCI Analytical Discovery Facility, which
houses two LC-MS and two LC-MS-MS (ion trap and QQQ). Oversight of equipment’s
maintenance and troubleshooting, method development and training of new personnel. Focus
on developing small molecules with biological interest, to target the endocannabinoid system for
therapeutic gain, in collaboration with California-based biotechnology start-up companies.

www.nanobiologicscorp.com
 Jul 2015-Present
Assistant Specialist. University of California, Irvine. Department of
Pharmacology. Piomelli lab. Lead optimization and pharmacological
characterization of peripheral
enzymatic inhibitors of the degradation of the endocannabinoid anandamide.

Sept 2012- Jun 2015

Postdoc Fellow. Italian Institute of Technology, Genoa, Italy. Drug Discovery and
Development department. Identification of the physiological mechanism responsible for the
restricted access of peripheral FAAH inhibitors to the Central Nervous System.

Sept 2010- Aug 2012

Fulbright Fellow. University of California, Irvine. Department of Pharmacology. Mentor,
Dr. Daniele Piomelli. Discovery of a new class of peripherally-restricted inhibitors of the
degradation of the endocannabinoid anandamide.
Sept 2008- Jun 2010
Graduate assistant, Complutense University of Madrid, Spain. Sept 2004- Sept 2008

www.nonobiologicscorp.com